Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bright Minds Biosciences Inc. (DRUG : NSDQ)

• Company Description    Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $63.14 Daily Weekly Monthly 20 Day Moving Average: 95,895 shares Shares Outstanding: 7.04 (millions) Market Capitalization: $444.76 (millions) Beta: -6.17 52 Week High: $79.02 52 Week Low: $23.18 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 18.51% 18.51% 12 Week 78.08% 70.73% Year To Date 75.29% 54.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 19 VESTRY STREET - NEW YORK,NY 10013 USA ph: 64-7407-2515 fax: - None http://www.brightmindsbio.com

• General Corporate Information    Officers Ian McDonald - President; Chief Executive Officer and Director Ryan Cheung - Chief Financial Officer Nils Christian Bottler - Director Jeremy Fryzuk - Director Jan Pedersen - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 10919W405 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 06/01/25 Next Expected EPS Date: 12/29/25 Share - Related Items Shares Outstanding: 7.04 Most Recent Split Date: 7.00 (0.20:1) Beta: -6.17 Market Capitalization: $444.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.98 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/29/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 11.87 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -1,425.00% vs. Previous Quarter: -82.76% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -20.96 03/31/25 - -10.91 ROA 09/30/25 - - 06/30/25 - -20.66 03/31/25 - -10.74 Current Ratio 09/30/25 - - 06/30/25 - 86.64 03/31/25 - 88.33 Quick Ratio 09/30/25 - - 06/30/25 - 86.64 03/31/25 - 88.33 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 5.32 03/31/25 - 5.51 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.12 03/31/25 - 0.16

Powered by Zacks Investment Research ©